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In peri-operative anesthetic practice,
complications occur frequently but are
rapidly identified and abated by astute
clinicians. Rarely, unexpected
complications such as MH develop and
require emergency intervention to
diminish the probability of mortality.
Malignant hyperthermia is a potentially
lethal hypermetabolic complication of a
rare inherited muscle disorder which is
caused by inhaled volatile anesthetics
and neuromuscular blocking agents.
(McCance & Huether, 2010, p. 500).
Understanding the susceptibility, risk
factors, pathophysiology, and treatment
are foundational for the advanced
practice nurse developing his practice,
but all clinicians must be knowledgeable
about MH so that evidenced-based
treatment may be swiftly implemented.
Quantifying MH events is challenging, but
that the prevalence for MH is 1 in
100,000 which differs from MH
susceptibility (MHS) of between 1 in
1,200 and 1 in 1,300 which may be
explained by sub-clinical manifestations
of MH crises. (Belani et al., 2020, p. 553)

Pathophysiological Processes
Pathophysiology
Signs & Symptoms
•

•

•

•

•

Inherited autosomal dominant
trait, more than 80 genetic defects
associated with MH (Spruce, 2020,
p. 282)
Genetic mutation RYR1 encodes
ryanodine receptors, CACNA1S
encodes dihydropyridine calcium
channels in skeletal muscle
(Nagelhout & Elisha, 2017, p. 774)
Reduced magnesium ion affinity
responsible for closing calcium
channels and triggering agents
greatly open RYRI channels leading
to uncontrolled, unopposed
calcium release from the
sarcoplasmic reticulum (Belani et
al., 2020, p. 553)
Sustained muscle contraction
consumes adenosine triphosphate
depleting stores leading to
“protracted muscle rigidity,
rhabdomyolysis and cellular
membrane breakdown releasing
intracellular contents (potassium,
CPK, and myoglobin into
circulation” (Schneiderbanger,
2014, n.p.)
Triggering agents include volatile
anesthetics (halothane, enflurane,
isoflurane, desflurane, sevoflurane)
and depolarizing neuromuscular
blocking agents, namely
succinylcholine (Schneiderbanger,
2014, n.p.)

Key Diagnostic Features
(Hopkins et al., 2021, p. 658)
•
•
•
•

Unexplained, unexpected rise in endtidal CO2 (ETCO2)
Unexplained, unexpected increase in
heart rate
Unexplained, unexpected increase in
temperature
Unexplained, unexpected skeletal
muscle rigidity

Pathogenesis: ExcitationContraction Coupling
Depolarizati

Other Diagnostic Features
(Hopkins et al., 2021, p. 660)
•
•
•
•
•
•
•
•

•
•

•

Sarcolemma
Transvers

•
•

Cardiac arrythmia
Cardiac arrest
Acidosis
Hyperkalemia
Rhabdomyolysis
Disseminated intravascular
coagulation (DIC)
Compartment syndrome
Masseter muscle rigidity

Nursing Implications

Risk Factors and
Genetics

•

Risk Factors
(Nagelhout & Elisha, 2017, p. 775)
Known MH susceptibility
Providers must use plain language
and consider healthcare literacy
when obtaining pre-operative
Family history of unexpected
intraoperative complications or
death
Family history of MH or MH-like
response to anesthesia
Genetics
Caffeine Halothane Contracture
Test is a muscle biopsy test for
establishing MHS (MHS) and is the
gold standard currently (Belani et
al., 2020)
Other genetic testing methods such
as next-generation sequencing are
being investigated to rule out MHS
but genetic counseling and CHCT
remain best-practice (Belani, et al.,
2020)

Reversing the MH Process
(Hopkins et al., 2021, p. 659)
•
•
•
•
•

•
•
•
•

•

Eliminate the agent (turn off/remove
vaporizer
Administer 100% Oxygen, maximal
flow
Increase minute ventilation 2-3x
normal
Insert activated charcoal filters into
inspiratory and expiratory limbs of
the circuit
Administer dantrolene sodium, 2.5
mg/kg as frequently as needed until a
decrease in ETCO2, decreased muscle
rigidity, and lowering heart rate are
appreciated (MHAUS, 2021)
Initiate active body cooling
Supportive therapy for other
symptoms
When body temperature rises above
41° C, DIC is the most common cause
of death (Gong, 2021, p. 7)
When dantrolene is unavailable, early
warning signs must be identified with
prompt, effective therapies (Gong,
2021, p. 7)
Providers should advocate for
dantrolene availability, even when
succinylcholine is used without
volatile anesthetics as MH crisis may
occur as demonstrated by Larach et
al. (2019)

Conclusion
MH is relatively rare, though
potentially fatal genetic condition that
requires prompt, effective treatment to
reduce mortality. This complexity
requires pre-operative identification,
thorough history and physical, a teambased treatment approach, and effective
communication. Anesthesia providers
are integral team members who must be
prepared with knowledge about MH and
need to be comfortable with the mixing
of dantrolene in a crisis.
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MH Resources
Malignant Hyperthermia
Association of the United States
24/7 Emergency MH Hotline
1(800)MH-HYPER (644-9737)
Figure 1: Retrieved from https://www.capnoacademy.com/

https://www.mhaus.org

Significance of Pathophysiology
Although MH has a relatively low incidence, the MH crisis patient is at a
heightened risk for death and all clinicians – especially anesthesia providers – in
the perioperative environment must be familiar with the signs, symptoms, and
protocols for treatment to reduce mortality.

Figure 2: Retrieved from https://www.dovepress.com/cr_data/article_fulltext/s47000/47632/img/fig1.jpg
(MHAUS, 2021)
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